Publications
Specialty
Search
Oncology
09/15/2024
Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with high-risk, early-stage triple-negative breast cancer.
Oncology
09/15/2024
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in HR-positive, HER2-positive early breast cancer.
Oncology
09/14/2024
Pembrolizumab plus chemoradiotherapy significantly improves OS compared to placebo plus chemoradiotherapy in patients with high-risk, locally advanced cervical cancer, according to a second interim analysis from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Oncology, IO Learning
09/14/2024
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular carcinoma.
Oncology
09/14/2024
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Oncology
09/14/2024
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Oncology
09/14/2024
Lothar Bergmann, MD, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of combination immunotherapy in patients with advanced non-clear cell renal cancers.
Oncology
09/14/2024
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Oncology
09/14/2024
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent non-small cell lung cancer.
EMSWorld
09/14/2024
Scott and Lisa DeBoer broadcast live from EMS World Expo 2024 in Las Vegas and interview Jonathan Merrell about a revolutionary BVM device designed to save lungs from overventilation.
Journal of Clinical Pathways
09/13/2024
A group of oncology practice innovators and care platform disruptors spoke about managing clinical and financial risk in oncology as part of a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
Pharmacy Learning Network
09/13/2024
Preferred Pharmaceuticals Inc. is recalling 266 bottles of ibuprofen tablets distributed in California and Nevada, according to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report. The affected tablets failed to meet impurity/degradation specifications during 18-month stability testing.
Pharmacy Learning Network
09/13/2024
Dr Reddy’s Laboratories Inc. is recalling 150 040 bottles of IBU (ibuprofen) tablets because of an unknown impurity. According to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report, testing revealed impurity results of 0.13% and 0.11%. The specification limit is 0.10%.
Pharmacy Learning Network
09/13/2024
Glenmark Pharmaceuticals Inc. USA is recalling 2404 bottles of indomethacin extended-release capsules distributed throughout the United States by Taro Pharmaceuticals USA, Hawthorne, New York. According to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report, samples failed to meet dissolution specifications during testing.
Neurology
09/13/2024
Intravenous Lu AG09222 reduced migraine frequency over 4 weeks in patients who had failed to find relief with previous treatments, according to a phase 2 trial published in the New England Journal of Medicine.
Psych Congress Network
09/13/2024
The United States Food and Drug Administration (FDA) has granted clearance for DaylightRx, a prescription digital therapeutic designed to treat generalized anxiety disorder (GAD).
Oncology
09/13/2024
Inhye Ahn, MD, shares insight into non-covalent BTK inhibitor pirtobrutinib treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy.
First Report Managed Care
09/13/2024
The US Department of Health and Human Services (HHS) has announced updates to Medicare payments and policies to improve healthcare accessibility, equity, and quality for millions of Americans, according to a press release by the HHS.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
